Correction: In vivo E2F reporting reveals efficacious schedules of MEK1/2–CDK4/6 targeting and mTOR–s6 resistance mechanisms (Cancer Discovery, 2018, 8, 1654)

Jessica L.F. Teh, Phil F. Cheng, Timothy J. Purwin, Neda Nikbakht, Prem Patel, Inna Chervoneva, Adam Ertel, Paolo M. Fortina, Ines Kleiber, Kim Hookim, Michael A. Davies, Lawrence N. Kwong, Mitch P. Levesque, Reinhard Dummer, Andrew E. Aplin

Research output: Contribution to journalComment/debatepeer-review

2 Scopus citations

Abstract

In the original version of this article (1), an error in Fig. 6C was introduced by the compositor during the production of the paper. Specifically, the Raptor Western blot was improperly shifted. The figure has been corrected in the latest online HTML and PDF versions of the article. The publisher regrets the error.

Original languageEnglish (US)
Pages (from-to)1654
Number of pages1
JournalCancer discovery
Volume8
Issue number12
DOIs
StatePublished - Dec 2018

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Correction: In vivo E2F reporting reveals efficacious schedules of MEK1/2–CDK4/6 targeting and mTOR–s6 resistance mechanisms (Cancer Discovery, 2018, 8, 1654)'. Together they form a unique fingerprint.

Cite this